Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation

Journal of Gastroenterology

Volumn 48, Issue 6, 2013, Pages 762-769

  Crespo, Gonzalo ^a   Carrión, José A ^a   Coto Llerena, Mairene ^a   Mariño, Zoe ^a   Lens, Sabela ^a   Pérez Del Pulgar, Sofía ^a   García Retortillo, Montserrat ^a   Miquel, Rosa ^a   Bosch, Jaime ^a   Navasa, Miquel ^a   Forns, Xavier ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Antiviral therapy; Cyclosporine A; IL28B; Liver transplantation; Sustained virological response

Indexed keywords

CYCLOSPORIN A; ERYTHROPOIETIN; GENOMIC DNA; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; AGGRESSION; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASCITES; CHRONIC GRAFT REJECTION; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DNA POLYMORPHISM; DRUG RESPONSE; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; GENE; GENOTYPE; GRAFT FAILURE; GRAFT SURVIVAL; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; IL28B GENE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INVASIVE ASPERGILLOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84879410933     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0680-2     Document Type: Article

References (35)

1. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680-7.
2. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29:250-6.
3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889-96.
4. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274-87.
5. Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transplant. 2006;12:1067-76.
6. Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodriguez M, Gentili F, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transplant. 2009;15:738-46.
7. Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transplant. 2009;15:782-9.
8. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zeinn NN. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transplant. 2008;14:53-8.
9. Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant. 2006;6:2348-55.
10. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007;46:459-65.
11. Berenguer M, Aguilera V, Rubin A, Ortiz C, Jimenez M, Prieto M. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol. 2012;56:1310-6.
12. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011;53:317-24.
13. Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, Carrión JA, Martínez SM, Sánchez-Tapias JM, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant. 2011;11:1051-7.
14. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010;139:1577-85, 1585.e1-3.
15. Lange CM, Moradpour D, Doehring A, Lehr HA, Mullhaupt B, Bibert S, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol. 2011;55:322-7.
16. Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transplant. 2011;17:289-98.
17. Carrion JA, Navasa M, Garcia-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132:1746-56.
18. Wiesner RH, Sorrell M, Villamil F, International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transplant. 2003;9:S1-9.
19. Ramirez S, Perez-Del-Pulgar S, Carrion JA, Costa J, González P, Massaguer A, et al. Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. Am J Transplant. 2009;9:1591-601.
20. Coto-Llerena M, Crespo G, Gonzalez P, Koutsoudakis G, Miquel R, Navasa M, et al. Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. J Hepatol. 2012;56:355-8.
21. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138:2307-14.
22. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
23. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:639-51.
24. Di Bona D, Cippitelli M, Fiorda C, Camma C, Licata A, Santoni A, et al. Oxidative stress inhibits IFN-α-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol. 2006;45:271-9.
25. ReVIS-TC Study Group. Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C infection: a large multicenter cohort study. Transplantation. 2011;92:334-40.
26. Selzner N, Renner EL, Selzner EL, Adeyi O, Kashfi A, Therapondos G, et al. Antiviral therapy of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009;88:1214-21.
27. Coilly A, Roche B, Botta-Fridlund D, Leroy V, Pageaux PG, Si-Ahmed SN, et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience. J Hepatol. 2012;56:S21.
28. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54:20-7.
29. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents - a potentially lethal cocktail. Hepatology. 2011;54:3-5.
30. Saxena V, Terrault N. Hepatitis C virus treatment in liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant. 2012;17:216-24.
31. Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev. 2010;(1):CD006803.
32. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8:679-87.
33. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008;8:2426-33.
34. Bizollon T, Pradat P, Mabrut JY, Chevallier M, Adham M, Radenne S, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant. 2005;5:1909-13.
35. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Ther Adv Gastroenterol. 2011;4:391-417.